TB-500 for Health & Longevity

Evidence Review created on 04/21/2026 using AI4L / Opus 4.7

Also known as: Thymosin Beta-4 Fragment, TB4 Frag (17-23), TB4-Frag, Synthetic Thymosin Beta-4 Analog, Tβ4 Active Site Peptide

Motivation

TB-500 is a synthetic peptide marketed in biohacking and sports-medicine circles as a “healing peptide” for soft-tissue injuries. It is widely described as thymosin beta-4, but it is actually a short synthetic fragment derived from the active region of the full 43-amino-acid thymosin beta-4 protein, re-engineered to improve solubility and stability. It is commonly injected under the skin and is often paired with BPC-157 in unregulated wellness protocols.

The parent protein thymosin beta-4 has been studied in human trials for tissue-repair uses, but no pharmaceutical form has received broad regulatory approval. The short TB-500 fragment sold as a “research peptide” has never been approved as a medication. The World Anti-Doping Agency prohibits it for competitive athletes, and in 2023 the U.S. Food and Drug Administration moved TB-500 onto a regulatory list that effectively prevents licensed compounding pharmacies from making it. Discussion is split between enthusiasts citing broad preclinical signals and skeptics citing thin human data and theoretical risks.

This review examines the available evidence on the peptide in adults, covering its proposed mechanism, expected benefits, potential risks, interactions, protocols, and monitoring considerations, and how current preclinical, clinical, and expert data inform its standing as a tissue-repair and longevity-oriented intervention.

Benefits - Risks - Protocol - Conclusion

Recommended Reading

This section lists high-level overview content discussing TB-500 and related tissue-repair peptide therapeutics in a health and longevity context.

• AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field - Peter Attia

  A long-form Ask Me Anything episode in which Peter Attia evaluates the peptide category including TB-500/thymosin beta-4, discussing the disconnect between broad clinical claims and thin human evidence, unknown long-term safety, and how he sorts peptides into risk–reward buckets for health-oriented adults.

• Benefits & Risks of Peptide Therapeutics for Physical & Mental Health - Andrew Huberman

  A full solo episode on peptide therapeutics in which Andrew Huberman discusses TB-500 alongside BPC-157 as commonly stacked tissue-repair peptides, reviewing their proposed mechanisms through actin sequestration and angiogenesis, typical wellness doses, and the theoretical tumor-growth concerns that accompany pro-angiogenic compounds.

Only two high-quality items from priority-expert platforms (Peter Attia, Andrew Huberman) were identified; dedicated, linkable articles or episodes from Rhonda Patrick (FoundMyFitness), Chris Kresser, and Life Extension Magazine specifically covering TB-500 or thymosin beta-4 in substantial depth could not be confirmed, so those priority experts are not represented rather than being padded with marginally relevant content.

Grokipedia

• Thymosin Beta-4

  The Grokipedia entry on thymosin beta-4 covers TB-500 as the synthetic 7-amino-acid fragment (Ac-LKKTETQ) derived from the actin-binding region of the full-length 43-amino-acid protein, its proposed actin-binding and angiogenic mechanisms, the distinction from full-length thymosin beta-4 in pharmaceutical development, and the current state of the clinical evidence — including the absence of large randomized trials for the TB-500 fragment specifically.

Examine

No Examine.com supplement profile for TB-500 or thymosin beta-4 was found as of 04/21/2026.

ConsumerLab

• BPC-157 and TB-500: Are These Compounds Safe and Effective Supplements?

  A ConsumerLab.com Q&A article covering TB-500 alongside BPC-157, explaining what TB-500 is marketed for, why it cannot legally be sold in the United States as a dietary supplement or approved drug, the gap between preclinical promise and human clinical evidence, and safety concerns tied to unregulated “research” sourcing.

Systematic Reviews

No systematic reviews or meta-analyses for TB-500 were found on PubMed as of 04/21/2026.

Mechanism of Action

TB-500 is a synthetic peptide derived from the active region of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid protein present in almost all mammalian cells. Most TB-500 products sold in the “research peptide” market correspond to a short fragment (commonly described as the Leu-Lys-Lys-Thr-Glu-Thr-Gln sequence or extended variants covering positions 17–23) encompassing the actin-binding site of thymosin beta-4, rather than the full-length protein itself. Marketing materials often conflate TB-500 with full-length thymosin beta-4, but the molecules differ in size, pharmacokinetics, and the breadth of supporting clinical data.

The most cited proposed mechanism of action is binding to G-actin, sequestering actin monomers and regulating actin polymerization — the same process that underpins cell migration, wound closure, and tissue remodeling. Downstream effects attributed to TB-500 and thymosin beta-4 include angiogenesis (growth of new blood vessels), recruitment of endothelial progenitor cells, fibroblast (connective-tissue cell) migration, and modulation of inflammatory signaling. Additional mechanisms reported in preclinical work include up-regulation of vascular endothelial growth factor (VEGF, a principal driver of new blood-vessel formation), activation of the Akt (protein kinase B, an intracellular signaling kinase that regulates cell survival and growth) and integrin-linked kinase pathways, anti-apoptotic effects on cardiomyocytes and neurons, and modulation of matrix metalloproteinases involved in tissue remodeling.

Competing mechanistic views exist. Proponents, including developers of full-length thymosin beta-4 products (RegeneRx Biopharmaceuticals and Sosei-Heptares under the RGN-259 and Timbetasin programs), characterize Tβ4 and its fragments as broadly pleiotropic “tissue-repair mediators” active across the eye, skin, heart, and central nervous system. Independent reviewers emphasize that most positive data come from animal models and from investigators with intellectual-property interests in the parent protein, that the specific TB-500 fragment has far less supporting evidence than full-length Tβ4, and that many preclinical findings have not been independently replicated in humans. A separate mechanistic concern is that pro-angiogenic and migration-promoting signaling — the same properties leveraged for tissue repair — are also exploited by many human cancers, so the peptide’s mechanism is not unambiguously benign.

Key pharmacological properties: TB-500 is a small peptide administered primarily by subcutaneous or intramuscular injection; oral absorption is poor due to peptide degradation in the gastrointestinal tract. It is not metabolized by hepatic cytochrome P450 (CYP, a family of liver enzymes that metabolize many drugs) enzymes and is broken down by plasma and tissue peptidases into smaller peptide fragments and amino acids. Plasma half-life in animal studies is short, on the order of 1–3 hours for the fragment and somewhat longer for full-length thymosin beta-4, although tissue effects persist beyond plasma presence. Tissue distribution in preclinical studies shows wide organ exposure, including musculoskeletal tissue, cardiac tissue, cornea, and skin. Selectivity at a single molecular receptor is not established; the G-actin interaction is the best-characterized molecular target.

Historical Context & Evolution

Thymosin beta-4 was first isolated from calf thymus in 1981 by Allan Goldstein and colleagues as part of the broader thymosin family of peptides. Over the subsequent decades it was identified as a ubiquitous intracellular actin-sequestering protein with roles in cell migration, angiogenesis, and wound healing, and explored in preclinical models of myocardial infarction, stroke, corneal injury, skin wounds, and neuroregeneration.

Clinical development focused on the full-length 43-amino-acid protein rather than the short TB-500 fragment. RegeneRx Biopharmaceuticals advanced thymosin beta-4 under the name RGN-259 through Phase 2 and Phase 3 trials for dry eye syndrome and into Phase 2 studies for neurotrophic keratopathy (a degenerative corneal disease caused by reduced nerve supply to the eye), alongside earlier Phase 2 work in venous stasis ulcers, pressure ulcers, and epidermolysis bullosa (a rare genetic blistering disorder). Sosei-Heptares pursued a related program in East Asia under the name Timbetasin. Results have generally shown modest signals of benefit with an acceptable short-term safety profile, but no product has received full regulatory approval in the United States or European Union as of 2025.

The short synthetic TB-500 fragment followed a different trajectory. Initially developed as a research tool to probe the actin-binding site of thymosin beta-4, it entered veterinary use — particularly in racehorse medicine — as an unapproved injectable for musculoskeletal injury, which led to its prohibition by racing regulators in multiple jurisdictions beginning in the 2010s. By the mid-2010s it had emerged in human biohacking and sports-medicine circles, typically obtained from “research chemical” vendors or, briefly, from compounding pharmacies.

Regulatory posture has tightened rather than loosened. The World Anti-Doping Agency has prohibited TB-500 at all times under its S2 category (peptide hormones, growth factors, related substances, and mimetics) and applies the prohibition across all competitive athletes. In September 2023 the U.S. Food and Drug Administration placed TB-500 on its Category 2 bulk substances list, effectively prohibiting licensed 503A and 503B compounding pharmacies from producing it. Published human clinical data specific to the synthetic TB-500 fragment — as distinct from the full-length thymosin beta-4 program — remain extremely limited. The claim that TB-500 has been “clinically proven” for tendon or muscle repair overstates the published human evidence for the fragment, while the claim that it has been “debunked” also overstates what rigorous trials of the fragment have actually tested.

Expected Benefits

Medium 🟩 🟩

Dry Eye and Corneal Wound Healing (Full-Length Thymosin Beta-4)

The strongest clinical evidence in the thymosin beta-4 family comes from ophthalmic use of the full-length parent protein RGN-259, not the short TB-500 fragment. Phase 2 and Phase 3 trials in dry eye syndrome have reported improvements in ocular surface staining, tear film stability, and patient-reported symptoms, with acceptable short-term tolerability. Phase 2 work in neurotrophic keratopathy has also been reported. These data inform expectations for the peptide family’s safety and proof-of-concept at the actin-binding mechanism, but they do not directly validate systemic injectable TB-500 fragment for musculoskeletal indications, and eye drops are not the route used in biohacking practice.

Magnitude: Approximately 30–50% relative improvement in ocular surface staining scores versus vehicle in dry-eye studies of full-length thymosin beta-4 eye drops.

Low 🟩

Musculoskeletal Injury Recovery (Tendon, Ligament, Muscle) ⚠️ Conflicted

Enthusiasm for TB-500 in sports-medicine and biohacking practice is driven primarily by preclinical rodent studies of full-length thymosin beta-4 showing faster healing of transected tendons, skeletal muscle injuries, and ligament repair, together with uncontrolled veterinary experience in racehorses. Direct human evidence for the synthetic TB-500 fragment in tendon, ligament, or muscle healing is limited to anecdotal clinical reports, small case series, and a handful of unpublished or poorly controlled studies; no adequately powered randomized controlled trials have been completed. The conflicted flag reflects the mismatch between confident marketing claims and the thinness of controlled human fragment data, and between strong mechanistic plausibility (actin sequestration, angiogenesis, cell migration) and the absence of independent human replication.

Magnitude: Not quantified in available studies.

Speculative 🟨

Cardiac Protection and Post-Infarction Repair

Preclinical work, including studies by Deepak Srivastava and collaborators at Gladstone and by RegeneRx-associated investigators, reports that systemic thymosin beta-4 reduces infarct size, promotes cardiomyocyte survival, supports epicardial progenitor activation, and improves ventricular function after experimental myocardial infarction in rodents and large-animal models. Human cardiovascular outcome data remain absent; the basis for this benefit is preclinical and mechanistic only.

Skin and Chronic Wound Healing

Preclinical and small early-phase clinical work with full-length thymosin beta-4 has suggested accelerated closure of venous stasis ulcers, pressure ulcers, and epidermolysis bullosa lesions. Results have generally been modest and no broadly approved product exists; for the synthetic TB-500 fragment specifically, human chronic wound data are largely absent. The basis is mechanistic and small early-phase parent-protein data.

Neurological and Neuroprotective Effects

Rodent studies report that thymosin beta-4 reduces injury and improves functional recovery in models of ischemic stroke, traumatic brain injury, spinal cord injury, and multiple sclerosis–like demyelination, with proposed actions on oligodendrocyte progenitor recruitment and neurite outgrowth. No rigorous human neurological outcome data exist; the basis is preclinical and mechanistic.

Hair Growth and Follicle Regeneration

Preclinical studies describe thymosin beta-4 promoting hair follicle stem cell migration and supporting follicle cycling; isolated anecdotal reports mention hair regrowth in TB-500 users. No controlled human trials for hair growth exist; the basis is preclinical and anecdotal.

Systemic Anti-Inflammatory Effects

Thymosin beta-4 has been reported to dampen inflammatory signaling in rodent models of sepsis, colitis, and autoimmune disease, and to modulate cytokine profiles in vitro. Human inflammatory biomarker data in adults using TB-500 are essentially absent; the basis is preclinical and mechanistic.

Longevity and Healthspan Extension

No human lifespan or healthspan outcome data exist for TB-500. Claims of general longevity benefit are inferred from its broad pro-regenerative profile in animal models and from user reports of improved recovery and function. The basis is speculative and mechanistic; it is included here because it is a commonly promoted — but unsupported — rationale for continuous or lifelong use.

Benefit-Modifying Factors

• Genetic polymorphisms: No well-validated genetic variants are currently known to meaningfully modify TB-500 response in humans. Because the peptide is not metabolized by hepatic cytochrome P450 enzymes and its primary molecular interaction (G-actin sequestration) is not routinely genotyped, standard pharmacogenetic variants (e.g., CYP2D6 (a liver enzyme that metabolizes roughly a quarter of common prescription drugs) and CYP3A4 (a liver enzyme responsible for metabolizing the largest share of prescription drugs); MTHFR (a folate-metabolism enzyme)) are unlikely to be primary drivers of response.
• Baseline biomarkers: Individuals with low baseline markers of tissue repair capacity (e.g., low ferritin, suboptimal vitamin D, low testosterone in men, poor glycemic control, elevated high-sensitivity C-reactive protein) may have more headroom for improvement, since TB-500’s proposed effects are additive to the body’s own healing substrate. Well-optimized baseline physiology may show smaller effects.
• Sex: TB-500 has not been systematically studied by sex. Known sex differences in tendon stiffness, collagen turnover, estrogen-modulated healing, and inflammatory signaling mean response could plausibly differ, but controlled human data to quantify differences do not exist.
• Pre-existing health conditions: Responses are most commonly described in populations with recent soft-tissue or joint injuries, chronic tendinopathy (persistent tendon pain and dysfunction), or chronic non-healing wounds; healthy adults using TB-500 “prophylactically” have essentially no evidence of benefit. Individuals with active or prior cancer are a specific sub-population in whom the pro-angiogenic, migration-promoting mechanism argues against use.
• Age: Older adults generally have slower tendon, muscle, skin, and cardiac repair, lower angiogenic capacity, and higher baseline inflammation, leaving more room for a healing peptide to have a detectable effect. Those at the older end of the target range are also more likely to harbor undiagnosed vascular disease or early neoplasia, where pro-migratory and pro-angiogenic signaling carries additional theoretical risk.
• Injury type and tissue vascularity: Preclinical work suggests thymosin beta-4 effects are most consistent in tissues with high demand for cell migration and remodeling (cornea, skin, tendon, myocardium); individuals treating a concrete injury may therefore notice more than those targeting generic “recovery.”
• Route of administration: Subcutaneous injection is the most common biohacking route; injection near the target tissue (subcutaneous or intramuscular) is often preferred by practitioners on the theory of improved local exposure. Oral preparations are uncommon because of expected degradation of the peptide in the gut; systemic parenteral dosing is the standard research route.
• Concurrent rehabilitation and loading: Effects on tendon and muscle healing depend on mechanical loading; integration with structured rehabilitation is likely to determine whether any peptide-mediated effect is clinically meaningful.

Potential Risks & Side Effects

Low 🟥

Injection Site Reactions

Local redness, itching, small bumps, soreness, or bruising at the subcutaneous or intramuscular injection site are the most commonly reported adverse effects in practical adult wellness use of TB-500 and usually resolve without intervention. Evidence comes from clinical case series, compounding-pharmacy reports, full-length thymosin beta-4 trial safety summaries, and routine practice reports.

Magnitude: Not quantified in available studies.

Speculative 🟨

Theoretical Tumor Growth or Metastasis Promotion ⚠️ Conflicted

TB-500’s best-established mechanism, actin sequestration with downstream pro-angiogenic, pro-migratory, and anti-apoptotic effects, substantially overlaps with properties many human cancers exploit. Mainstream commentators including Andrew Huberman and Peter Attia caution that pro-angiogenic, migration-promoting peptides could in principle support growth or metastatic spread of existing tumors. Developers of full-length thymosin beta-4 (RegeneRx and collaborators) have argued that clinical trial data show no increased cancer signal, but cohorts have been small and short. No human oncology outcome data exist for the TB-500 fragment; the basis is mechanistic plausibility and theoretical concern rather than documented cases.

Unknown Long-Term Safety

The synthetic TB-500 fragment has never undergone large, long-term controlled safety trials in healthy adults. Full-length thymosin beta-4 clinical data are modest in size, usually short in duration, and in different indications and formulations. Potential delayed or rare adverse effects of months-to-years use remain essentially uncharacterized; the basis is the absence of evidence rather than positive reports of harm.

Immunogenicity and Allergic Reactions

The FDA has cited immunogenicity — production of antibodies against an administered peptide — as a concern motivating TB-500’s Category 2 classification. Isolated reports of injection-site flare, systemic hypersensitivity, and non-specific malaise exist but are difficult to interpret given variable product quality; the basis is regulatory guidance and isolated reports.

Product Impurity and Contamination

A substantial portion of TB-500 available to end users comes from “research chemical” suppliers marketed “not for human use,” which are not held to pharmaceutical manufacturing standards. Documented problems include incorrect peptide content (often shorter or different fragments than labelled), endotoxin contamination, bacterial contamination from non-sterile reconstitution, and undeclared ingredients; the basis is FDA and Department of Defense Operation Supplement Safety briefings, racing-commission testing reports, and repeated third-party testing failures in the unregulated supply.

Cardiovascular and Hemodynamic Effects

Some preclinical and anecdotal reports describe transient blood-pressure changes, palpitations, or dizziness following injection. Thymosin beta-4 modulates vascular endothelium and has pro-angiogenic effects; no controlled human hemodynamic data for the fragment exist; the basis is preclinical reports and uncontrolled case reports.

Interaction With Proliferative Conditions

Because TB-500 and thymosin beta-4 support angiogenesis, cell migration, and anti-apoptotic signaling, they could theoretically interact unfavorably with proliferative conditions such as diabetic retinopathy, wet age-related macular degeneration, active neoplasia, uncontrolled psoriasis, or endometriosis; the basis is mechanistic only.

Fatigue and “Flu-Like” Symptoms

Isolated user reports describe transient fatigue, mild flu-like symptoms, or “head-fog” in the first few days of dosing. These reports are uncontrolled, may reflect product impurities or immune response rather than the peptide itself, and have not been systematically investigated; the basis is anecdotal reports only.

Anti-Doping Positive Tests

For athletes subject to World Anti-Doping Agency rules, use of TB-500 itself is a prohibited-substance violation under class S2 (peptide hormones, growth factors, related substances, and mimetics). Contamination of unrelated supplements with TB-500 has been documented in racing and sports contexts. The consequence is not a pharmacologic adverse effect but a career- and sanctions-level risk; the basis is regulatory.

Risk-Modifying Factors

• Genetic polymorphisms: No well-validated variants are currently known to specifically alter TB-500 risk. Because TB-500 is a small peptide not metabolized by hepatic CYP enzymes, common pharmacogenetic variants (e.g., CYP2D6, CYP3A4, VKORC1 — a vitamin K epoxide reductase variant affecting warfarin sensitivity) are not a primary safety driver. Genetic predisposition to hormone-sensitive or angiogenesis-driven cancers (e.g., BRCA1/2 carriers — inherited mutations in breast-cancer susceptibility genes; Lynch syndrome — an inherited condition that raises risk of colorectal and several other cancers; strong family history of cancer) is, however, a reasonable consideration given the theoretical pro-angiogenic and pro-migratory mechanism.
• Baseline biomarkers: Abnormal baseline hemoglobin, liver enzymes, kidney function, fasting glucose, or inflammatory markers may shift the risk profile by signaling underlying pathology that could interact unpredictably with a broadly pleiotropic peptide; screening labs help identify such cases before starting.
• Sex-based differences: TB-500 has not been systematically studied by sex; no definitive sex-specific risk differences are established. Women of reproductive age should treat the absence of pregnancy safety data as an absolute consideration.
• Pre-existing health conditions: Active or prior cancer (particularly solid tumors with high angiogenic dependence such as renal cell, ovarian, hepatocellular, colorectal, and melanoma), proliferative diabetic retinopathy, active wet age-related macular degeneration, endometriosis, and recent stroke are the most important “reasons not to use,” given the pro-angiogenic and pro-migratory mechanism. Active autoimmune disease with unpredictable flares is a secondary concern.
• Pregnancy and breastfeeding: No safety data exist; TB-500 should be avoided.
• Age and frailty: Older, frail adults, including those at the older end of the target range, are more likely to harbor undiagnosed early neoplasia or vascular disease, which amplifies the theoretical risks of a pro-angiogenic peptide; they also tend to have less physiologic reserve to tolerate unexpected adverse effects.
• Competitive or tested-athlete status: Any athlete in a sport governed by World Anti-Doping Agency rules should treat TB-500 as an absolute prohibition, regardless of source or formulation.
• Source of product: Using unregulated “research chemical” TB-500 markedly increases contamination and dosing risk relative to pharmaceutical-grade product. Since the 2023 U.S. FDA Category 2 designation, legitimate 503A/503B compounding of TB-500 in the United States is effectively prohibited, shifting more supply to unregulated channels.
• Veterinary product substitution: Veterinary TB-500 products (sold for racehorses before regulatory prohibition) are sometimes repurposed by individuals; these are not manufactured to human pharmaceutical standards and carry higher impurity, endotoxin, and labeling-error risks.

Key Interactions & Contraindications

• Antiangiogenic cancer therapies (prescription, e.g., bevacizumab, ramucirumab, sunitinib, sorafenib, lenvatinib): TB-500 is proposed to promote angiogenesis and cell migration, directly opposing the mechanism of VEGF-pathway inhibitors used in oncology. Severity: absolute contraindication in patients on active antiangiogenic therapy. Mitigation: avoid combination entirely; consequence is potential blunting of cancer therapy.
• Anticoagulants and antiplatelet agents (prescription, e.g., warfarin, apixaban, rivaroxaban, clopidogrel; and OTC aspirin): Thymosin beta-4 may modulate endothelial function and coagulation in preclinical models; theoretical effects on bleeding are unpredictable. Severity: caution. Mitigation: avoid initiating TB-500 during active therapeutic anticoagulation without physician oversight.
• Growth hormone and growth-hormone secretagogues (prescription, e.g., somatropin, ibutamoren/MK-677): TB-500 is commonly stacked with growth hormone or secretagogues for “recovery” in biohacking practice; theoretical amplification of proliferative signaling is plausible but not characterized clinically. Severity: caution. Mitigation: avoid stacking without specialist oversight, especially in anyone with cancer risk factors.
• Immunomodulators and immunosuppressants (prescription, e.g., prednisone, dexamethasone, methotrexate, tacrolimus, biologics such as adalimumab or infliximab): Systemic corticosteroids and other immunosuppressants blunt the inflammation–resolution signaling that TB-500 is proposed to modulate, and may alter peptide immunogenicity. Severity: monitor. Mitigation: time TB-500 trials away from active immunosuppressive courses when possible.
• Non-steroidal anti-inflammatory drugs (NSAIDs; OTC, e.g., ibuprofen, naproxen, high-dose aspirin): NSAIDs may impair tendon and muscle healing; combining with TB-500 could blunt the peptide’s proposed healing effect and complicate attribution. Severity: monitor. Mitigation: minimize chronic NSAID use during a TB-500 trial.
• Peptide stacks (e.g., BPC-157, GHK-Cu, thymosin alpha-1, tesamorelin, ipamorelin, CJC-1295): Biohacking practice commonly stacks TB-500 with other peptides, particularly BPC-157; interaction data are essentially nonexistent, and stacking compounds attribution, sourcing risk, and immunogenic exposure. Severity: monitor. Mitigation: introduce only one new peptide at a time.
• Supplements with additive angiogenic, proliferative, or growth-factor-like effects (e.g., high-dose IGF-1 (insulin-like growth factor 1, a hormone that drives tissue growth and repair) boosters, deer antler velvet products, colostrum at high doses, high-dose creatine in very high exercise loads): Additive signaling is plausible but unquantified. Severity: monitor. Mitigation: avoid routine stacking.
• Estrogens and selective estrogen receptor modulators (prescription, e.g., oral contraceptives, hormone replacement therapy, tamoxifen, raloxifene): No specific pharmacologic interaction is documented, but estrogen status modulates wound healing and breast tissue proliferation; caution is reasonable in individuals using hormonal therapy, particularly in the context of breast-cancer history or risk. Severity: monitor.
• Alcohol and recreational stimulants: No specific pharmacologic interaction is documented, but heavy alcohol use impairs tissue healing and complicates interpretation of any peptide trial. Severity: monitor.
• Populations who should avoid TB-500 (absolute contraindications/caution):
  • Pregnant or breastfeeding women (no safety data)
  • Children and adolescents (no safety data)
  • Individuals with active or recently treated cancer (< 5 years), especially angiogenesis-dependent solid tumors (e.g., renal cell, ovarian, hepatocellular, colorectal, melanoma)
  • Individuals with known genetic high cancer risk (e.g., BRCA1/2 carriers, Lynch syndrome)
  • Individuals with proliferative diabetic retinopathy or active wet age-related macular degeneration
  • Individuals with active endometriosis or a history of hormone-sensitive gynecologic malignancy
  • Individuals with recent stroke (< 90 days) or recent myocardial infarction (< 90 days)
  • Competitive or tested athletes subject to World Anti-Doping Agency rules
  • Individuals with known hypersensitivity to the peptide or excipients in the preparation

Risk Mitigation Strategies

• Screen for cancer and high cancer risk first: Confirm age-appropriate cancer screening is up to date (e.g., colonoscopy per guidelines, mammography, Pap (Papanicolaou cervical smear)/HPV (human papillomavirus) testing, skin exam, PSA (prostate-specific antigen, a blood marker used in prostate cancer screening) if appropriate) and avoid TB-500 in anyone with active cancer, recent cancer (< 5 years), or high-penetrance hereditary cancer syndromes; this mitigates the theoretical pro-angiogenic tumor-promotion risk.
• Confirm anti-doping eligibility: Any athlete subject to World Anti-Doping Agency or similar rules should treat TB-500 as prohibited and not use it; this mitigates the career-level sanctions risk, which is independent of pharmacologic safety.
• Use only for a defined injury or indication: Limit use to a specific, identifiable soft-tissue injury, tendinopathy, or non-healing wound with a concrete endpoint (e.g., return-to-sport goal within 8–12 weeks); this mitigates indefinite low-benefit exposure.
• Time-limit the course: Most wellness protocols limit continuous loading use to 4–6 weeks followed by reduced maintenance dosing, with total annual exposure kept low (e.g., < 16 weeks/year on maintenance) to mitigate unknown long-term safety risk.
• Source with maximum rigor: Since the 2023 U.S. FDA Category 2 designation, legitimate 503A/503B compounding of TB-500 in the United States is effectively prohibited. Where used outside those jurisdictions or under specialist research protocols, require a certificate of analysis confirming peptide identity (mass spectrometry), purity (typically ≥ 98%), correct peptide sequence (distinguishing true TB-500 fragment from full-length Tβ4 or unrelated peptides), and endotoxin testing; avoid any “research chemical not for human use” or veterinary-labeled supplier. This directly mitigates contamination, impurity, and incorrect-content risk.
• Start low and observe: Begin at the lower end of commonly reported wellness doses (e.g., 2 mg once weekly subcutaneous) before titrating, to observe injection-site tolerance and systemic effects.
• Rotate injection sites and use sterile technique: Rotate sites weekly, use single-use syringes and alcohol prep, and reconstitute with bacteriostatic water stored refrigerated to minimize local reactions and infection risk.
• Keep a structured response log: Record pain scores, functional measures (e.g., range of motion, specific loaded-tendon tests, wound dimensions), and any side effects weekly for 6–8 weeks; this enables honest assessment and mitigates indefinite use without benefit.
• Reassess at a defined endpoint: At 4 and 8 weeks, decide explicitly whether to continue, cycle to maintenance, or stop; if no meaningful objective or functional change, discontinue. This mitigates open-ended exposure to an incompletely characterized agent.
• Medical oversight for higher-risk users: Individuals on anticoagulants, with significant cardiovascular disease, with endocrine or autoimmune conditions, or with personal or family cancer history should use TB-500 only under clinician oversight with periodic review; this mitigates unpredictable interactions and adverse events in higher-risk users.
• Do not substitute veterinary or gray-market product: Explicitly avoid veterinary TB-500 products and “research chemical not for human use” vials; these have documented labeling, purity, and endotoxin problems that directly drive adverse events.

Therapeutic Protocol

There is no approved or evidence-based standardized protocol for TB-500 in humans. In biohacking and sports-medicine practice, the most commonly reported approach is subcutaneous injection of 2–2.5 milligrams once or twice weekly as a “loading” phase for 4–6 weeks, followed by a maintenance phase of 2–2.5 milligrams every 2–4 weeks for a further 4–8 weeks, for a total course of roughly 8–12 weeks. Some protocols use higher initial loading doses (e.g., 5 milligrams twice weekly) for 2–4 weeks before maintenance, particularly in sports-medicine contexts with a specific injury. Injections are typically placed subcutaneously in the abdomen or near the target tissue. Intramuscular injection is also used. Oral preparations are uncommon because of expected peptide degradation in the gut, and have less supporting data than parenteral use.

Competing approaches exist. Peptide-focused clinicians associated with organizations such as Seeds Scientific Performance Research (William Seeds, author of the Peptide Protocols handbook series) and the International Peptide Society have popularized structured TB-500 protocols for tendon and muscle injuries, generally emphasizing a loading–maintenance structure with injection near the target tissue. A more conservative stance, common among U.S. sports-medicine physicians and mainstream rehabilitation specialists, treats TB-500 as insufficiently validated, legally restricted since the 2023 FDA Category 2 action, and preferentially substitutes evidence-based rehabilitation, eccentric loading programs, platelet-rich plasma (PRP) where indicated, and surgical management for anatomic lesions. A third approach, reflected in Peter Attia’s and Andrew Huberman’s public commentary, treats TB-500 as an experimental tool to be used sparingly, if at all, and only in clearly defined injury contexts with cancer risk screened out.

• Best time of day: No strong time-of-day signal exists; most protocols dose consistently at the same time of day when injections are scheduled, often in the evening to minimize any transient local discomfort during daily activities.
• Half-life: TB-500 has a short plasma half-life in the range of 1–3 hours for the fragment in animal studies, while full-length thymosin beta-4 has a somewhat longer apparent half-life; tissue effects appear to outlast plasma presence, which supports once- or twice-weekly dosing despite the short plasma residence.
• Single vs. split dosing: Most protocols use a single weekly or twice-weekly dose rather than daily dosing, reflecting the longer duration of biological effect versus plasma half-life. Some split 5 milligrams weekly into 2 × 2.5 milligrams; others use a single weekly 2–2.5 milligram dose. Evidence to favor one regimen is not rigorous.
• Genetic considerations: No well-established pharmacogenetic variants are known to meaningfully alter TB-500 dosing. Commonly discussed variants such as APOE4 (an apolipoprotein E variant associated with cardiovascular and Alzheimer’s risk), MTHFR (a folate-metabolism enzyme variant), and COMT (a catecholamine-degrading enzyme variant) have no established role in TB-500 response.
• Sex-based differences: Not systematically studied; no formal sex-based dose differences are used. Women of reproductive age should not use TB-500 during pregnancy or breastfeeding due to absence of safety data.
• Age considerations: Older adults, including those at the older end of the target range, should start at the lower end of the dose range and weigh the theoretical neoplastic risk more heavily, given higher background incidence of undiagnosed early cancer and greater prevalence of vascular pathology.
• Baseline biomarkers: No biomarker is validated as a dose-guiding measure for TB-500; objective and subjective healing at the treated tissue are the main response indicators.
• Pre-existing conditions: Active or recent cancer, known high cancer risk, proliferative retinopathy, active endometriosis, and recent vascular events argue against use.

Discontinuation & Cycling

TB-500 is not intended as a lifelong intervention; available data, however limited, support short, injury-specific courses rather than continuous use. No specific withdrawal syndrome is described, and stopping TB-500 is not known to cause rebound injury or symptoms. Tapering is not required given the short plasma half-life; abrupt discontinuation is well tolerated in reported practice, although the loading–maintenance protocol structure inherently tapers exposure over time. Cycling approaches — typically a 4–6 week loading phase, 4–8 weeks of maintenance, then 8–12 weeks off before any repeat course — are the most commonly reported structure, intended to limit cumulative exposure to an incompletely characterized agent rather than to preserve efficacy per se. Once a defined injury endpoint is reached, discontinuation rather than indefinite maintenance dosing is the more defensible default given the limited long-term safety data and theoretical concerns around continuous pro-angiogenic signaling.

Sourcing and Quality

• Regulatory status and availability: TB-500 is not an approved medication in the United States, European Union, United Kingdom, Canada, Australia, or most other major jurisdictions. In September 2023 the U.S. Food and Drug Administration placed TB-500 on its Category 2 bulk substances list, effectively prohibiting 503A and 503B compounding pharmacies from producing it; as of 2026 it cannot be legally obtained through U.S. compounding pharmacies.
• Implications of the Category 2 designation: Category 2 under sections 503A/503B of the U.S. Federal Food, Drug, and Cosmetic Act means the FDA has determined the substance raises significant safety concerns and should not be compounded. Products marketed in the United States as TB-500 are typically sold as “research chemicals not for human use,” as dietary supplements (which is itself contrary to FDA guidance), or through clinics obtaining material outside the legal compounding pathway.
• Veterinary products are not a substitute: TB-500 historically marketed for veterinary use in racehorses is not manufactured to human pharmaceutical standards and has been prohibited by many racing authorities; it should not be used by humans regardless of apparent cost advantage.
• Distinguish TB-500 fragment from full-length thymosin beta-4: Full-length thymosin beta-4 is in clinical development under names such as RGN-259 and Timbetasin (primarily as an eye drop and topical preparation); the synthetic TB-500 fragment is a distinct molecule with a separate evidence base. Product labels and marketing often conflate the two; a legitimate certificate of analysis should specify the exact peptide sequence.
• Non-U.S. jurisdictions: Availability outside the United States varies; some jurisdictions still allow compounding or research use, but commercial pharmaceutical approval does not exist anywhere for the synthetic fragment.
• What to look for when a legitimate supply exists: Require a certificate of analysis confirming peptide identity (mass spectrometry), the exact sequence of the TB-500 fragment, purity (typically ≥ 98%), endotoxin content below pharmaceutical thresholds, and correct peptide content.
• Preferred forms: Lyophilized peptide vials reconstituted with bacteriostatic water for injection and administered by fine-gauge subcutaneous syringe. Storage: lyophilized vials refrigerated and protected from light; reconstituted vials used within the facility-specified window (often 28 days) and kept refrigerated.
• Reputable suppliers: Prior to the 2023 Category 2 action, U.S. compounders such as Empower Pharmacy, Tailor Made Compounding, and Olympia Pharmaceuticals were common sources; most have now removed TB-500 from their catalogues. Where TB-500 is used today outside regulated research protocols, it is generally not possible to identify a source that is simultaneously legal in the United States, accredited, and quality-controlled.
• Avoid gray-market “research chemical” suppliers: A substantial portion of TB-500 sold online is marketed as “research chemical not for human use,” is unregulated, frequently of uncertain purity or sequence, and should be avoided regardless of price. Third-party testing has repeatedly documented incorrect content, impurities, and contamination in such products.

Practical Considerations

• Time to effect: Reported tendon, ligament, and muscle-injury responses typically begin within 2–3 weeks and plateau by 6–8 weeks of a loading-plus-maintenance course; chronic wound or ocular-surface responses in full-length thymosin beta-4 trials have been reported within 4–8 weeks. A substantial minority of biohacking users report no detectable effect.
• Common pitfalls: Using TB-500 in place of structured rehabilitation (eccentric loading, progressive loading, physical therapy, wound care), sourcing from unregulated or veterinary suppliers, confusing the synthetic fragment with full-length thymosin beta-4 clinical data, stacking with multiple other peptides simultaneously, dosing inconsistently, continuing indefinitely without a defined endpoint, ignoring pre-existing cancer risk, using it while subject to anti-doping testing, and attributing natural injury resolution to the peptide.
• Regulatory status: Not approved for any indication. As of 2023, placed in U.S. FDA Category 2 for compounding, which effectively closes the licensed compounding pathway in the United States. World Anti-Doping Agency-prohibited for competitive athletes under class S2. Prohibited by most horse-racing authorities. Legal frameworks differ internationally; where TB-500 is obtained outside regulated channels, it often falls outside legal pharmaceutical supply chains.
• Cost and accessibility: Where available, reported monthly costs range from roughly $150 to $500 depending on dose, source, and frequency; access in the United States is highly restricted after the 2023 Category 2 action. Gray-market sources are cheaper but carry significant quality and legal risk.

Interaction with Foundational Habits

• Sleep: Indirect. TB-500 is not a sleep-active peptide, but impaired sleep blunts tissue healing, angiogenesis, and immune-resolution signaling — the same processes TB-500 is proposed to support. Practical considerations: aim for consistent 7–9 hours nightly, with a stable bedtime window, during any TB-500 trial; sleep-disrupting behaviors (late caffeine, evening alcohol) will oppose peptide effects regardless of dose.
• Nutrition: Direct and potentiating. Adequate protein intake (roughly 1.2–1.6 g/kg/day in adults) supports collagen, skin, and muscle synthesis, on which TB-500’s proposed effects depend; vitamin C, zinc, vitamin A, and adequate energy intake also support wound and tendon healing. Heavy ultra-processed intake, chronic caloric deficit, and poor glycemic control oppose the same pathways. Practical considerations: hit protein targets across meals, include collagen-rich foods or 10–15 g hydrolyzed collagen around rehabilitation sessions, and maintain adequate vitamin C (> 90 mg/day in men, > 75 mg/day in women) and zinc; correct iron deficiency before starting.
• Exercise: Potentiating if integrated into structured rehabilitation, blunting if used as a substitute. TB-500’s proposed effects on tendon, ligament, and muscle healing depend on appropriate mechanical loading; using the peptide in the absence of progressive loading largely forgoes its plausible benefit. Practical considerations: pair any TB-500 trial with a structured eccentric or isometric loading program appropriate to the injury (e.g., Alfredson protocol for Achilles tendinopathy, heavy slow resistance for patellar tendinopathy), under physical-therapy guidance; avoid high-impact loading that exceeds the tissue’s current tolerance.
• Stress management: Indirect. Chronic psychological stress elevates cortisol, suppresses tissue healing, and increases systemic inflammation, all of which oppose the mechanisms TB-500 is proposed to support. Practical considerations: incorporate a specific daily stress-reduction practice (e.g., 10 minutes of slow breathing, mindfulness, or walking outdoors) during the healing course; chronic unmanaged stress will likely overwhelm any peptide-level effect.

Monitoring Protocol & Defining Success

Because TB-500 is not a hormone or metabolic modulator, there is no single laboratory biomarker that tracks its effects. Baseline testing before starting is used primarily to screen for conditions that would argue against use (particularly cancer risk and uncontrolled cardiometabolic disease) and to identify correctable factors that would blunt any benefit (e.g., iron deficiency, low vitamin D, poor glycemic control). Ongoing monitoring is dominated by tissue-specific functional and symptom measures rather than blood tests.

Ongoing monitoring follows a simple cadence: weekly symptom and function tracking (pain scores, range of motion, loaded function tests specific to the injury, wound dimensions where applicable) throughout the course; a structured re-evaluation at 4 weeks and again at 8 weeks to decide whether to continue, transition to maintenance, or stop; age-appropriate cancer screening maintained on its usual schedule (not accelerated, but not deferred); and baseline labs repeated at 6–12 months if the peptide is used repeatedly.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
CBC with differential	Within standard reference ranges	Screens for unexplained anemia, leukocytosis, or thrombocytosis that could signal occult disease	CBC stands for complete blood count. Fasting not required. Recheck annually or before each new course.
CMP (liver and kidney)	Within standard reference ranges	General safety monitoring; TB-500 is cleared by plasma and tissue peptidases	CMP stands for comprehensive metabolic panel, a standard blood test covering electrolytes, kidney, and liver markers. Fasting recommended. Recheck annually.
hs-CRP	< 1.0 mg/L	Elevated systemic inflammation blunts tissue healing and may suggest undiagnosed disease	hs-CRP stands for high-sensitivity C-reactive protein. Avoid during acute illness or within 2 weeks of infection. Recheck annually.
Ferritin	50–150 ng/mL	Low iron stores impair tissue repair, collagen synthesis, and endurance	Conventional “normal” extends much lower; functional target is higher. Recheck annually, or every 3–6 months if supplementing iron.
25-OH Vitamin D	40–60 ng/mL	Vitamin D status correlates with tendon, muscle, and skin repair	Measured as serum 25-hydroxyvitamin D. Recheck every 6–12 months.
HbA1c	< 5.3%	Dysglycemia impairs tendon and wound healing and raises cancer risk	HbA1c stands for glycated hemoglobin, a measure of average blood sugar over ~3 months; conventional “normal” extends to 5.6%. Recheck annually.
Fasting insulin and fasting glucose	Insulin < 8 µIU/mL; glucose 70–90 mg/dL	Insulin resistance blunts tissue repair	Fasting 10–12 hours. Recheck annually.
Age-appropriate cancer screening	Up to date per current guidelines	TB-500’s pro-angiogenic, pro-migratory mechanism argues against use in active or undiagnosed cancer	Includes colonoscopy, mammography, Pap/HPV, dermatology exam, and PSA where indicated. Maintain on normal schedule.
Testosterone (men)	Mid to upper age-adjusted reference range	Low testosterone impairs muscle and tendon repair	Morning draw, fasting. Recheck annually if being addressed.
Thyroid panel (TSH, Free T4)	TSH 1.0–2.0 mIU/L; Free T4 mid-range	Hypothyroidism impairs healing and energy	TSH stands for thyroid-stimulating hormone; Free T4 is free (unbound) thyroxine, the circulating active thyroid hormone fraction. Morning draw. Recheck annually.
Lipid panel	Within standard functional range	Underlying vascular disease may be relevant given pro-angiogenic mechanism	Fasting 10–12 hours. Recheck annually.

Qualitative and functional markers are the primary measure of success for TB-500:

• Pain at the treated tissue (e.g., a simple 0–10 visual analog scale daily or weekly)
• Loaded-function tests specific to the injury (e.g., single-leg hop, heel-raise endurance, grip strength, loaded tendon provocation tests)
• Range of motion at the relevant joint
• Wound dimensions and re-epithelialization, where applicable (for chronic wound or ulcer indications)
• Return-to-activity milestones (walking distance, running tolerance, lifting capacity, sport-specific drills)
• Sleep quality and perceived recovery
• Overall sense of function and well-being

Success is best defined as meaningful and durable improvement in pain, function, or wound healing at the treated tissue within 6–8 weeks, without adverse effects; absence of meaningful objective or functional change after a 6–8 week trial is a strong argument for discontinuation rather than escalation.

Emerging Research

• Full-length thymosin beta-4 in neurotrophic keratopathy (NCT05555589): SEER-2, a Phase 3 randomized, placebo-controlled trial of 0.1% RGN-259 (full-length thymosin beta-4 eye drops) in neurotrophic keratopathy, sponsored by ReGenTree, LLC; primary endpoints include corneal defect closure and ocular surface staining. Results inform the parent peptide’s clinical signal, although the ophthalmic route differs from biohacking subcutaneous use.
• Thymosin beta-4 for dry eye syndrome (NCT03937882): ARISE-3, a Phase 3 trial of RGN-259 in dry eye syndrome, sponsored by ReGenTree, LLC; primary endpoints include ocular surface staining and symptom scores. Together with the earlier ARISE-1 (NCT02597803) and ARISE-2 (NCT02974907) programs, its outcomes continue to shape regulatory perception of the thymosin beta-4 family.
• Thymosin beta-4 in epidermolysis bullosa: Early-phase programs for systemic and topical thymosin beta-4 in epidermolysis bullosa wound healing have been pursued by RegeneRx and collaborators; further trial readouts would strengthen or weaken the wound-healing claim.
• Peptide therapeutics in sports and orthopaedic medicine (Mendias & Awan, 2026): A 2026 review in Sports Medicine evaluating approved and unapproved peptide therapies, including TB-500, which provides an up-to-date external perspective on safety and efficacy claims; its positioning of TB-500 among other “unapproved” peptides is likely to shape clinician attitudes.
• Thymosin beta-4 mechanistic work in cardiac repair (Smart et al., 2007): The Oxford group’s demonstration that thymosin beta-4 induces adult epicardial progenitor mobilization and neovascularization remains foundational; future cardiac outcome trials, if undertaken, could meaningfully change the clinical picture.
• Regulatory evolution — FDA Category 2 and legal challenges: Continued litigation from compounding stakeholders challenging the 2023 U.S. Food and Drug Administration Category 2 designation for peptides, including TB-500 and BPC-157, could, in principle, change the legal availability landscape; the trajectory of such litigation is itself an emerging research/regulatory direction worth tracking alongside the Mendias & Awan 2026 review above.
• Independent replication of TB-500 musculoskeletal effects: A rigorous, adequately powered, placebo-controlled randomized trial of the synthetic TB-500 fragment for tendon or muscle injury has not been completed; such a trial would be the most important single input to the human evidence base and could shift the peptide from “speculative/low” to a firmer evidence level in either direction.
• General literature tracking: Updated literature can be tracked via PubMed.

Conclusion

TB-500 is a synthetic peptide fragment derived from the active region of thymosin beta-4 and marketed for tissue repair. The strongest clinical evidence in the thymosin beta-4 family lies in eye-drop use of the full-length parent protein, not the injectable fragment sold in biohacking circles; direct human evidence for the TB-500 fragment in tendon, ligament, muscle, or wound healing is limited to anecdotal reports and small case series. Broader claims about cardiac, neurological, skin, hair, and longevity effects rest on animal work and mechanism rather than rigorous human outcome data. Much of the supporting research is concentrated among investigators with ownership interests in thymosin beta-4, a conflict that warrants weight when interpreting positive claims.

Short-term risks in published use of the peptide family have been modest and dominated by injection-site reactions, but long-term safety for the fragment is effectively unknown. Its best-established mechanism — promoting cell migration, new blood-vessel growth, and cell-survival signaling — overlaps with pathways many cancers exploit, keeping a plausible theoretical concern alive. Regulatory posture has tightened: TB-500 is not approved anywhere, is prohibited for competitive athletes, and U.S. compounding access has effectively closed.

The available evidence positions this peptide as an experimental, niche option for carefully selected adults with a specific soft-tissue injury, no meaningful cancer history, no anti-doping exposure, and access to a high-quality product; its role in longevity per se is not supported by human outcome data.

Top - Benefits - Risks - Protocol